MYELO-CAN Platform

Protocol #: CHI-001

Title: Evaluation of supportive care treatments among outpatients with myelodysplastic syndrome and acute myeloid leukemia: a multicenter pilot trial (MYELO-CAN)

Description: Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are serious, life changing blood cancers associated with significant morbidity and mortality. Morbidity is to a large extent due to anemia, neutropenia and thrombocytopenia (i.e. bone marrow failure). Despite the need for supportive care interventions such as transfusions and antimicrobials to manage these patients, evidence-informed outpatient supportive care strategies are lacking to prevent the most common adverse events (eg: bleeding and infection).

Aim: The primary objective is to build clinical trial platform infrastructure to create a patient-centred learning health system to advance knowledge and improve patient outcomes, quality-of-life and survival in patients with MDS and AML.

Endpoints: This platform is intended to host trials focused on various aspects of MDS and AML care at different phases of investigation. Therefore, we cannot specify a single primary endpoint for the entire platform.